S-1: 180 Life Sciences Corp. Files for $5 Million Offering of Common Stock and Warrants

180 Life Sciences Corp. announces a proposed public offering of up to $5 million in common stock and warrants to fund research and development, general corporate purposes, and strategic transactions.

Summary

• 180 Life Sciences Corp. has filed a Form S-1 registration statement for a proposed public offering.
• The offering includes up to $5 million of common stock, pre-funded warrants, and common warrants.
• Each share of common stock or pre-funded warrant will be sold with a common warrant to purchase additional shares.
• The assumed public offering price is $_____ per share, based on the last reported sales price on Nasdaq on July __, 2024.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits of 4.99% or 9.99%.
• The company intends to use the net proceeds for research and development expenses, general corporate purposes, transaction costs to complete a reverse-merger and legal expenses.
• The offering will terminate no later than _____, 2024, but shares underlying the warrants will be offered continuously.
• The company's common stock is listed on Nasdaq under the symbol ATNF.
• The company is currently evaluating all options to monetize its existing assets, in addition to exploring other strategic alternatives to maximize value for its stockholders.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the offering aims to raise capital, the company's financial situation, Nasdaq compliance issues, and potential dilution raise concerns.

Positives

• The offering aims to raise capital for research and development, general corporate purposes, transaction costs to complete a reverse-merger and legal expenses.
• The company is exploring strategic alternatives to maximize value for its stockholders.

Negatives

• There is no established public trading market for the pre-funded warrants and common warrants.
• The company may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received by the company.
• The company is not in compliance with the continued listing standards of Nasdaq and Nasdaq has provided a delisting determination letter; the company may not be able to comply with Nasdaqs continued listing standards in the future, and as a result the company's Common Stock and Public Warrants may be delisted from Nasdaq.
• The company's current cash balance is only expected to be sufficient to fund its planned business operations through approximately October 2024.

Risks

• Investors will experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• The company may not raise the amount of capital it believes is required for its business plans.
• The company is a clinical stage biotechnology company that had no revenue for the three months ended March 31, 2024, and for the years ended December 31, 2023 and 2022, and do not anticipate generating revenue for the near future.
• The company will need additional capital which may not be available on commercially acceptable terms, if at all, which raises questions about the company's ability to continue as a going concern.
• The company may not receive any further amount under its pre-merger directors and officers insurance policy in connection with certain litigation matters.
• The market price of the company's Common Stock has been extremely volatile and may continue to be volatile due to numerous circumstances beyond the company's control.
• The company is not in compliance with the continued listing standards of Nasdaq and Nasdaq has provided a delisting determination letter; the company may not be able to comply with Nasdaqs continued listing standards in the future, and as a result the company's Common Stock and Public Warrants may be delisted from Nasdaq.

Future Outlook

The company intends to use the net proceeds from the sale of its securities under this prospectus for research and development expenses and general corporate purposes, transaction costs to complete a reverse-merger and legal expenses.

Industry Context

The biotechnology industry is capital-intensive, and companies often require public offerings to fund research and development activities.

Comparison to Industry Standards

• Many clinical-stage biotech companies pursue public offerings to raise capital, a common practice in the industry.
• Comparable companies in the biotech sector, such as [Competitor A] and [Competitor B], have also utilized similar financing strategies to fund their operations and clinical trials.
• The terms of the offering, including the use of warrants, are consistent with industry standards for companies in a similar stage of development.

Legal Proceedings

• AmTrust International Underwriters DAC filed a declaratory relief action against the company.
• The company filed an answer and counterclaims against AmTrust for bad faith breach of insurance coverage obligations.
• The company brought a third-party complaint against Freedom Specialty Insurance Company.
• The Court granted the Companys Motion for Partial Summary Judgment against both AmTrust and Freedom, and ordered as follows: (a) AmTrust is obligated under its insurance policy with the Company to advance to the Company all defense costs in excess of the deductible that the Company has advanced, or will advance, to Dr. Krauss and Mr. Hornig in connection with certain SEC Subpoenas, and (b) upon exhaustion of the AmTrust insurance policy, Freedom is obligated to do the same pursuant to its excess liability insurance policy with the Company.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The offering could provide the company with additional resources to advance its research and development programs.
• The company's ability to regain compliance with Nasdaq listing requirements is crucial for maintaining investor confidence.

Next Steps

• The company will determine the final offering price and terms with the placement agent and investors.
• The company will proceed with the offering, subject to market conditions and regulatory approvals.
• The company will use the net proceeds for the stated purposes.
• The company and Amtrust have a mediation conference scheduled for August 21, 2024, during which, the parties could agree on a settlement agreement.
• The Company intends to continue to vigorously pursue the matter in order to establish the Company's entitlement to full and final payment by both AmTrust and Freedom of the subject advancement expenses of the Company.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, biotechnology, ATNF, capital raise, research and development, strategic alternatives, 180 Life Sciences